Company Profile

Asklepios Biopharmaceutical Inc (AKA: AskBio~VectorRx Inc)
Profile last edited on: 6/17/2021      CAGE: 47AH9      UEI: EMHJLKNXNYY6

Business Identifier: Adeno-associated virus (AAV) gene therapies for genetic disorders
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

870 Martin Luther King Jr Boulevard
Chapel Hill, NC 27514
   (919) 968-2727
Location: Single
Congr. District: 04
County: Orange

Public Profile

In October 2020, it was announced that Bayer had acquired AskoBio to broaden the larger firm's innovation base in cell and gene therapy. Formerly dba as VectorRX Inc, Asklêpios BioPharmaceutical Inc., (and adba AskBio) Asklepios BioPharmaceutical, Inc. (AskBio) had been founded to take advantage of the deep gene therapy resources in the Research Triangle Park area. With global headquarters in Research Triangle Park, NC and a stroing European presence with staff and facilities headquarters in Edinburgh, UK, the company has generated hundreds of proprietary third-generation AAV capsids and promoters, several of which have entered clinical testing. With focus on gene therapy clinical development and delivery of novel protein and cellular based therapies through design of proprietary Biological Nano Particles (BNP) the firm has achieved a portfolio of intellectual property in gene therapy for multiple disease and an advanced manufacturing process, AskBio has established and formed industry alliances for multiple spin out companies and continues to pursue new gene therapy technologies and treatments.isth a strong program of out-licensing and building on a previous business, Portfolio companies including NanoCor Therapeutics: partnered with Medtronic to develop treatments for heart failure; Chatham Therapeutics was sold to Baxter to develop hemophilia treatments; and Bamboo Therapeutics was sold to Pfizer to develop cures for rare neuromuscular diseases and muscular dystrophy. In the 18 months prior to its own acqusirion, Asklepios had embarked o n an acqusition strategy of its own acquiring three other small firms withrelated soeciality and capabilities to its own.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $270,008
Project Title: AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
2010 1 NIH $2,999,988
Project Title: Self-Complementary AAV2 Factor IX for Hemophilia B
2008 2 NIH $320,999
Project Title: Preclinical Studies Supporting Phase Ib Study of Minidystrophin Gene in AAV Vecto
2008 1 NIH $282,210
Project Title: Preclinical Development Of Aav-Galanin For Epilepsy
2005 1 NIH $157,070
Project Title: rAAV Revitalized Structural Allografts

Key People / Management

  Shelia Mikhail -- Co-Founder Chief Executive Officer, President

  David C Venables -- President Europe

  Martin K Childers -- Chief Medical Officer

  Robin Fastenau -- Vice President, Communications

  Josh Grieger -- Chief Technology Officer

  Don Haut -- Chief Business Officer

  Tim Kelly -- President, Manufacturing

  Ken Macnamara -- COO

  Ken Macnamara -- Chief Operating Officer, AskBio Europe

  Scott McPhee -- Vice President, Research & Development

  Philippe Moullier -- Chief Scientific Officer, AskBio Europe

  Luke Roberts

  Michael Roberts -- Chief Technology Officer, AskBio Europe

  R Jade Samulski -- Vice President, Business Development

  Richard J Samulski -- Scientific Co-founder

  Kellie Sears -- Chief Human Resources Officer

  Candace Summerford -- Chief Patent Office

  Xiao Xiao -- Scientific Co-Founder